DEG6498

Phase 1Small molecule

DDegron Therapeutics Co.

DEG6498 is one of 15 small molecule programs targeting Malignant Neoplasm. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Malignant NeoplasmRecruiting

Malignant NeoplasmPhase 1

Recruiting

Competition

Competitive Landscape

18 competitors in Malignant Neoplasm

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

2 2

Aromasin

Pfizer

Phase 2

1 3

Nolvadex

AstraZeneca

Phase 2

1 4

Femara

Novartis

Phase 2

1 5

Erbitux

IImclone

Phase 2

1 6

Paraplatin

AAvyxa

Phase 2

1 7

Alimta

GGynecologic Oncology Group

Phase 2

1 8

Faslodex

FFresenius Kabi Oncology Ltd.

Phase 2

1 9

Rescue Medications

Merck & Co.

Phase 2

1 10

Opevesostat

Merck & Co.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Malignant Neoplasm

NCT07244835

Clinical

Trials by Indication[1]

Malignant Neoplasm1 trial

A First in Human Phase 1 Open-Label, Multicenter, Dose Escalation and Expansion Study of DEG6498 in Patients With Solid Tumors

Recruiting·DDegron Therapeutics Co.·Phase 1·NCT07244835·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DEG6498. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DEG6498 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DEG6498. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Degron Therapeutics Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: DDegron Therapeutics Co.

DEG6498

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Malignant Neoplasm1 trial

References

Drug Info

Quick Facts

Related News